Tuesday, August 30, 2011

Keating Capital Backs Metabolon

Greenwood Village, Colorado-based Keating Capital, an investor in private companies, said today that it was the lead investor in a funding round for Metabolon, a firm developing molecular diagnostics services and technology. Keating said it led a $13M, Series D investment round for Metabolon, which also included Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners. Keating's share of the investment was worth $4M. Metabolon is based in Research Triangle Park, North Carolina. The firm's molecular diagnostics are aimed at detecting and measuring the aggression and stage of diseases such as diabetes and cancer. More information »